23rd August 2016. Vyome Biosciences, a clinical-stage specialty biopharmaceutical company developing medicines for treating skin diseases caused by resistant microbes, has received $14 million (approx Rs 93 crore) Series-C funding, led by Perceptive Advisors, a New York based life sciences fund and, Romulus Capital, a Boston-based VC firm, along with participation from existing investors including Kalaari Capital, Sabre Partners and Aarin Capital.
"The company will utilise these funds predominantly to advance the clinical development of its lead product and continue to develop other proprietary products in the pre-clinical stage," said Venkateswarlu Nelabhotla, CEO, Vyome Biosciences.
Vyome's VB 1953 targets the antibiotic resistant acne market. The company will soon be initiating clinical studies in the USA. Apart from lead program VB 1953, Vyome also has a pipeline of pre-clinical products that can fight the development of resistance based on its patented technology.
Copyright © 2015 Vyome Therapeutics Inc. All rights reserved.